Home | Founder | What's New | In The News | Consulting | |||||||
H1N1 Consulting Paradigm Shift Intervention Monitoring |
Audio:Jan21
Feb2
Feb13 Feb18
twitter
Live feed of underlying pandemic map data here Commentary
The
above comments and additional media remarks strongly suggest that E627K
has been detected in at least three
patients in India. Although there have
previous reports of E627K in Shanghai
and The
Netherlands, the earlier reports were in the first and second waves
in the northern hemisphere, when there was little selective pressure
because wild type H1N1 was spreading rapidly. However,
at the start of the third wave, there is significantly more pressure
because of the establishment of immunity to wild type pandemic H1N1 in
a significant percentage of the target population. E627K
increases polymerase activity at lower temperatures and therefore
favors increased replication in the mammalian upper respiratory tract. All human flu since 1918 has had E627K,
further supporting its selective advantage. The
presence of E627K in three patients signals transmission, and it is
likely that E627K will become much more common in the upcoming weeks. The
start of a new wave in the northern hemisphere leads to increases in a
range of genetic changes. Increases in
G158E, D225G/N and H274Y have been noted and such increases are likely
to accelerate in the third wave in the northern hemisphere. E627K
can lead to higher levels in the upper respiratory tract and more
efficient infections associated with higher viral loads.
An increase in viral load can significantly impact the
course and severity of the infection. When
H1N1 jumps species, as seen in pandemic H1N1, there are a series of
adaptations that lead to more efficient replication and spread in the
new host species. E627K is a modification
that is linked to efficient growth and spread in humans. Thus, the report of E627K in three patients in India is significant and cause for concern. Media LinksRecombinomics
Presentations |
||||||||||
|
Webmaster:
webmaster@recombinomics.com
© 2010
Recombinomics. All
rights
reserved.